Optimization of Naltrexone Diclofenac Codrugs for Sustained Drug Delivery Across Microneedle-treated Skin

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2013 Aug 15

PMID 23943543

Citations 1

Authors

Priyanka Ghosh

DoMin Lee

Kyung Bo Kim

Audra L Stinchcomb

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this work was to optimize the structure of codrugs for extended delivery across microneedle treated skin. Naltrexone, the model compound was linked with diclofenac, a nonspecific cyclooxygenase inhibitor to enhance the pore lifetime following microneedle treatment and develop a 7 day transdermal system for naltrexone.

Methods: Four different codrugs of naltrexone and diclofenac were compared in terms of stability and solubility. Transdermal flux, permeability and skin concentration of both parent drugs and codrugs were quantified to form a structure permeability relationship.

Results: The results indicated that all codrugs bioconverted in the skin. The degree of conversion was dependent on the structure, phenol linked codrugs were less stable compared to the secondary alcohol linked structures. The flux of naltrexone across microneedle treated skin and the skin concentration of diclofenac were higher for the phenol linked codrugs. The polyethylene glycol link enhanced solubility of the codrugs, which translated into flux enhancement.

Conclusion: The current studies indicated that formulation stability of codrugs and the flux of naltrexone can be enhanced via structure design optimization. The polyethylene glycol linked naltrexone diclofenac codrug is better suited for a 7 day drug delivery system both in terms of stability and drug delivery.

Citing Articles

Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.

Li Z, Fang X, Yu D Int J Mol Sci. 2021; 22(23).

PMID: 34884558 PMC: 8657870. DOI: 10.3390/ijms222312754.

References

Ran Y, He Y, Yang G, Johnson J, Yalkowsky S . Estimation of aqueous solubility of organic compounds by using the general solubility equation. Chemosphere. 2002; 48(5):487-509. DOI: 10.1016/s0045-6535(02)00118-2. View

Verebey K, Volavka J, MULE S, Resnick R . Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976; 20(3):315-28. DOI: 10.1002/cpt1976203315. View

Brogden N, Milewski M, Ghosh P, Hardi L, Crofford L, Stinchcomb A . Diclofenac delays micropore closure following microneedle treatment in human subjects. J Control Release. 2012; 163(2):220-9. PMC: 3725617. DOI: 10.1016/j.jconrel.2012.08.015. View

ABELIN T, Buehler A, Muller P, Vesanen K, Imhof P . Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet. 1989; 1(8628):7-10. DOI: 10.1016/s0140-6736(89)91671-1. View

Henry S, McAllister D, Allen M, Prausnitz M . Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998; 87(8):922-5. DOI: 10.1021/js980042+. View

Milewski M, Stinchcomb A . Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res. 2010; 28(1):124-34. DOI: 10.1007/s11095-010-0191-x. View

Wermeling D, Banks S, Hudson D, Gill H, Gupta J, Prausnitz M . Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A. 2008; 105(6):2058-63. PMC: 2538880. DOI: 10.1073/pnas.0710355105. View

Oesch F, Fabian E, Oesch-Bartlomowicz B, Werner C, Landsiedel R . Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev. 2007; 39(4):659-98. DOI: 10.1080/03602530701690366. View

Kalluri H, Banga A . Formation and closure of microchannels in skin following microporation. Pharm Res. 2010; 28(1):82-94. DOI: 10.1007/s11095-010-0122-x. View

10.

Milewski M, Pinninti R, Stinchcomb A . Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin. J Pharm Sci. 2012; 101(8):2777-86. DOI: 10.1002/jps.23189. View

11.

Milewski M, Yerramreddy T, Ghosh P, Crooks P, Stinchcomb A . In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release. 2010; 146(1):37-44. PMC: 2916235. DOI: 10.1016/j.jconrel.2010.05.034. View

12.

Burton S, Ng C, Simmers R, Moeckly C, Brandwein D, Gilbert T . Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm Res. 2010; 28(1):31-40. PMC: 3003827. DOI: 10.1007/s11095-010-0177-8. View

13.

McCaul M, Wand G, Rohde C, Lee S . Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res. 2000; 24(9):1385-91. View

14.

Vaddi H, Banks S, Chen J, Hammell D, Crooks P, Stinchcomb A . Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J Pharm Sci. 2008; 98(8):2611-25. PMC: 2764244. DOI: 10.1002/jps.21594. View

15.

Prusakiewicz J, Ackermann C, Voorman R . Comparison of skin esterase activities from different species. Pharm Res. 2006; 23(7):1517-24. DOI: 10.1007/s11095-006-0273-y. View

16.

Stinchcomb A, Swaan P, Ekabo O, Harris K, Browe J, Hammell D . Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J Pharm Sci. 2002; 91(12):2571-8. DOI: 10.1002/jps.10239. View

17.

Banks S, Paudel K, Brogden N, Loftin C, Stinchcomb A . Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm Res. 2011; 28(5):1211-9. PMC: 3377386. DOI: 10.1007/s11095-011-0372-2. View

18.

Potts R, Guy R . A predictive algorithm for skin permeability: the effects of molecular size and hydrogen bond activity. Pharm Res. 1995; 12(11):1628-33. DOI: 10.1023/a:1016236932339. View

19.

Lau W, White A, Gallagher S, Donaldson M, McNaughton G, Heard C . Scope and limitations of the co-drug approach to topical drug delivery. Curr Pharm Des. 2008; 14(8):794-802. DOI: 10.2174/138161208784007653. View

20.

Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L . PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2006; 35(1):9-16. DOI: 10.1124/dmd.106.012419. View